statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dyne Therapeutics reported promising Phase 1/2 trial data for DYNE-101 in myotonic dystrophy type 1 and DYNE-251 in Duchenne muscular dystrophy. Improvements in splicing correction, myotonia, muscle...

Why Is Dyne Therapeutics Stock Soaring On Monday?

Oppenheimer restated their outperform rating on shares of Dyne Therapeutics (NASDAQ:DYN  Free Report) in a research report report published on Tuesday morning, Benzinga reports. The firm...

Dyne Therapeutics (NASDAQ:DYN) Earns "Outperform" Rating from Oppenheimer

WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...

Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium

Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer

John Cox

 John Cox, President and CEO of Dyne Therapeutics

- John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO...

Dyne Therapeutics Announces CEO Transition

Citigroup Inc. raised its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN  Free Report) by 22.8% in the 3rd quarter, according to the company in its most recent disclosure with the...

Citigroup Inc. Has $555,000 Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN)

This price move could be a signal that DYN may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Dyne Therapeutics (DYN, $29.18) price may drop as it broke higher Bollinger Band on Mar 21, 2024

Investors in Dyne Therapeutics Inc (DYN) saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DYN...

First Week of May 17th Options Trading For Dyne Therapeutics (DYN)

Dyne Therapeutics, Inc. (NASDAQ:DYN  Get Free Report) SVP Richard William Scalzo sold 2,672 shares of Dyne Therapeutics stock in a transaction dated Monday, March 11th. The stock was sold at...

Dyne Therapeutics, Inc. (NASDAQ:DYN) SVP Sells $67,548.16 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN  Get Free Report) COO Susanna Gatti High sold 2,292 shares of Dyne Therapeutics stock in a transaction that occurred on Monday, March 11th. The shares were...

Dyne Therapeutics, Inc. (NASDAQ:DYN) COO Susanna Gatti High Sells 2,292 Shares

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Watchers	2,325
52-Wk Low	$6.40
52-Wk High	$35.98

Volume	6.69M
52-Wk High	$35.98
52-Wk Low	$6.40

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.73	--	--	N/A
Q1'24	-$0.80	-$0.81	-1.25%	MISSED
Q4'23	-$0.90	-$1.09	-21.62%	MISSED
Q3'23	-$0.83	-$0.99	-18.92%	MISSED
Q2'23	-$0.81	-$1.08	-33.76%	MISSED

DYN Dyne Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals